Literature DB >> 2829760

Major liver resection for hilar cholangiocarcinoma.

S Bengmark1, H Ekberg, A Evander, B Klofver-Stahl, K G Tranberg.   

Abstract

Between 1968 and 1984 liver resection with curative attempt was performed in 22 patients with hilar cholangiocarcinoma. Right lobectomy was performed in 4 patients, extended right lobectomy in 7, left lobectomy in 8, and excision of the median segment segment of the left lobe (segment IV) in 3. Bilio-enteric continuity was restored by hepatocholedochostomy in 17 patients and hepatojejunostomy in 4. (One patient had external transhepatic catheter drainage and no internal bile drainage.) Operative mortality rate was 27% and caused by excessive intraoperative bleeding, sepsis, or liver insufficiency. Postoperative complications occurred in 57% of patients surviving the operation and were due mainly to leakage from the hepatocholedochostomy. Median survival was 6 months, and one third of the patients survived 1 year. Three patients survived 10 years and were among the four patients in whom a tumor-free resection margin was obtained (one of them died in the postoperative phase). It is concluded that resection of hilar cholangiocarcinoma may give long-term survival if a free resection margin is obtained. The importance of a free resection margin indicates that surgery should be aggressive and include liver resection.

Entities:  

Mesh:

Year:  1988        PMID: 2829760      PMCID: PMC1493364          DOI: 10.1097/00000658-198802000-00002

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  17 in total

1.  MALIGNANT OBSTRUCTION OF THE MAJOR HEPATIC DUCTS.

Authors:  J K QUATTLEBAUM; J K QUATTLEBAUM
Journal:  Ann Surg       Date:  1965-06       Impact factor: 12.969

2.  Primary carcinoma of the extrahepatic bile-ducts.

Authors:  D B BROWN; R STRANG; J GORDON; E B HENDRY
Journal:  Br J Surg       Date:  1961-07       Impact factor: 6.939

3.  Carcinoma of the bile ducts.

Authors:  B THORBJARNARSON
Journal:  Cancer       Date:  1959 Jul-Aug       Impact factor: 6.860

4.  The hepatic ducts, a surgical approach for resection of tumour.

Authors:  G BROWN; N MYERS
Journal:  Aust N Z J Surg       Date:  1954-05

5.  Surgical approaches to cholangiocarcinoma at confluence of hepatic ducts.

Authors:  L H Blumgart; N S Hadjis; I S Benjamin; R Beazley
Journal:  Lancet       Date:  1984-01-14       Impact factor: 79.321

6.  Carcinoma of the extrahepatic bile ducts: results of an aggressive surgical approach.

Authors:  J C Langer; B Langer; B R Taylor; R Zeldin; B Cummings
Journal:  Surgery       Date:  1985-10       Impact factor: 3.982

7.  Pathological aspects of cholangiocarcinoma.

Authors:  K Weinbren; S S Mutum
Journal:  J Pathol       Date:  1983-02       Impact factor: 7.996

8.  Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver.

Authors:  H Bismuth; M B Corlette
Journal:  Surg Gynecol Obstet       Date:  1975-02

9.  Evaluation of aggressive surgery for carcinoma of the extrahepatic bile ducts.

Authors:  A Evander; P Fredlund; J Hoevels; I Ihse; S Bengmark
Journal:  Ann Surg       Date:  1980-01       Impact factor: 12.969

10.  Relief of bileduct obstruction by the percutaneous transhepatic insertion of an endoprosthesis.

Authors:  J S Dooley; R Dick; D Irving; J Olney; S Sherlock
Journal:  Clin Radiol       Date:  1981-03       Impact factor: 2.350

View more
  36 in total

1.  Management strategies in resection for hilar cholangiocarcinoma.

Authors:  H Bismuth; R Nakache; T Diamond
Journal:  Ann Surg       Date:  1992-01       Impact factor: 12.969

2.  Preoperative biliary drainage before resection for cholangiocarcinoma (Pro).

Authors:  Y Nimura
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

3.  Proximal bile duct cancer: high resectability rate and 5-year survival.

Authors:  B Launois; J Terblanche; M Lakehal; J M Catheline; E Bardaxoglou; S Landen; J P Campion; F Sutherland; B Meunier
Journal:  Ann Surg       Date:  1999-08       Impact factor: 12.969

Review 4.  Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making.

Authors:  Irinel Popescu; Traian Dumitrascu
Journal:  Langenbecks Arch Surg       Date:  2014-05-20       Impact factor: 3.445

5.  Percutaneous transhepatic portal embolization using newly devised catheters: preliminary report.

Authors:  M Nagino; Y Nimura; N Hayakawa
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

6.  Surgical treatment of hilar bile duct carcinoma: experience with 25 consecutive hepatectomies.

Authors:  Yoshifumi Kawarada; Bidhan C Das; Tatsushi Naganuma; Masami Tabata; Hiroki Taoka
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

7.  Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate.

Authors:  Yasuji Seyama; Keiichi Kubota; Keiji Sano; Tamaki Noie; Tadatoshi Takayama; Tomoo Kosuge; Masatoshi Makuuchi
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

8.  Combined portal vein resection for hilar cholangiocarcinoma: a meta-analysis of comparative studies.

Authors:  Xiang-Song Wu; Ping Dong; Jun Gu; Mao-Lan Li; Wen-Guang Wu; Jian-Hua Lu; Jia-Sheng Mu; Qi-Chen Ding; Lin Zhang; Qian Ding; Hao Weng; Ying-Bin Liu
Journal:  J Gastrointest Surg       Date:  2013-04-17       Impact factor: 3.452

9.  Is parenchyma-preserving hepatectomy a noble option in the surgical treatment for high-risk patients with hilar bile duct cancer?

Authors:  Hiroshi Shimada; Itaru Endo; Mitsutaka Sugita; Hideki Masunari; Yoshiro Fujii; Kuniya Tanaka; Hitoshi Sekido; Shinji Togo
Journal:  Langenbecks Arch Surg       Date:  2003-02-28       Impact factor: 3.445

10.  Frozen section and permanent diagnoses of the bile duct margin in gallbladder and bile duct cancer.

Authors:  Koji Yamaguchi; Kengo Shirahane; Masafumi Nakamura; Dongming Su; Hiroyuki Konomi; Kentaro Motoyama; Atsushi Sugitani; Kazuhiro Mizumoto; Masao Tanaka
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.